Carbidopa High-Dose — Competitive Intelligence Brief

Carbidopa High-Dose (Carbidopa High-Dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aromatic L-amino acid decarboxylase inhibitor. Area: Movement Disorders.

phase 2 Aromatic L-amino acid decarboxylase inhibitor Aromatic L-amino acid decarboxylase Movement Disorders Small molecule

Target snapshot

Carbidopa High-Dose (Carbidopa High-Dose) — NYU Langone Health. Carbidopa is a decarboxylase inhibitor that prevents the conversion of levodopa to dopamine, thereby increasing the availability of levodopa in the brain.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Carbidopa High-Dose TARGET	Carbidopa High-Dose	NYU Langone Health	phase 2	Aromatic L-amino acid decarboxylase inhibitor	Aromatic L-amino acid decarboxylase
Sinemet (comparator)	Sinemet (comparator)	XenoPort, Inc.	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic L-amino acid decarboxylase (AADC); dopaminergic system
Levodopa + benserazide	Levodopa + benserazide	University of Buenos Aires	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Dopamine pathway; aromatic L-amino acid decarboxylase (peripheral inhibition)
Levodopa and carbidopa	Levodopa and carbidopa	NeuroDerm Ltd.	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Dopamine pathway; aromatic L-amino acid decarboxylase (inhibited by carbidopa)
Madopar monotherapy	Madopar monotherapy	Peking University Third Hospital	marketed	Dopamine precursor / Decarboxylase inhibitor combination	Dopamine pathway; aromatic L-amino acid decarboxylase (peripheral inhibition by benserazide)
Accordion Pill™ Carbidopa/Levodopa	Accordion Pill™ Carbidopa/Levodopa	Intec Pharma Ltd.	phase 3	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic L-amino acid decarboxylase (carbidopa); dopamine pathway (levodopa)
IR CD-LD	IR CD-LD	Impax Laboratories, LLC	phase 3	Dopamine replacement therapy / Decarboxylase inhibitor combination	Dopamine pathway; carbidopa inhibits aromatic L-amino acid decarboxylase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aromatic L-amino acid decarboxylase inhibitor class)

1. NYU Langone Health · 2 drugs in this class